The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers
Phase 1
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: [14C]VC005
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 6
- Registration Number
- NCT06974292
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: VC005 groupsDrug: VC005 Placebo group
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 114
- Registration Number
- NCT06891040
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital of Skin Disease, Nanjing, Jiangsu, China
Phase III Clinical Study of VC005 Tablets in Adult Patients with Moderate to Severe Atopic Dermatitis
Phase 3
Recruiting
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: VC005 low dose groupDrug: VC005 high dose groupDrug: VC005 Placebo group
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 480
- Registration Number
- NCT06723080
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital for Skin Diseases, Nanjing, Jiangsu, China
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Phase 3
Recruiting
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- Drug: VC004 Capsules
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06658353
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 56
- Registration Number
- NCT06619951
- Locations
- 🇨🇳
Zhongda Hospital,Affiliated to Southeast University, Nanjing, Jiangsu, China
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Phase 3
Recruiting
- Conditions
- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 1000
- Registration Number
- NCT06577519
- Locations
- 🇨🇳
General Hospital of Northern Theater Command of Chinese PLA, Shenyang, Liaoning, China
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
- Interventions
- Drug: Median Dose VC004 CapsulesDrug: High Dose VC004 CapsulesDrug: Low Dose VC004 Capsules
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT06529445
- Locations
- 🇨🇳
Zhongda Hospital,Affiliated to Southeast University, Nanjing, Jiangsu, China
Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 80
- Registration Number
- NCT06009094
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital of Skin Disease, Nanjing, Jiangsu, China
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase 2
Completed
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: VC005 tabletsDrug: VC005 Tablets Placebo
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 149
- Registration Number
- NCT05997927
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital for Skin Diseases, Nanjing, Jiangsu, China
A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: VC005 Tablets PlaceboDrug: VC005 tablets
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 30
- Registration Number
- NCT05874622
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
© Copyright 2025. All Rights Reserved by MedPath